Why healthcare is the last industry to go digital -- and what's finally changing

Marc Andreessen famously declared that "software is eating the world." Finance transformed. Retail transformed. Logistics transformed. Healthcare, somehow, kept saying no -- until now. In a recent episode of From Lab to Life, four-time entrepreneur Mariano Valenio, CEO of digital health company Xenia, laid out exactly why this industry has resisted -- and what's finally breaking the logjam.

The insights are deeply relevant to anyone building or selling software into life sciences. And they point to a fundamental shift that Qualio has built its entire platform around: the move from reactive compliance to continuous, proactive execution.

Healthcare was designed for a different disease

Valenio's diagnosis is precise. The modern healthcare system was designed in the 1940s and '50s -- NHS, the first US health plans, the whole architecture -- to fight acute diseases. Infections. Clear symptoms. Obvious paths to the doctor. And for decades, it worked remarkably well.

"We managed to gain like 30 years of life through that system. But the bad thing is that now we have time to develop other diseases -- and those are mostly chronic diseases." -- Mariano Valenio, CEO of Xenia

Chronic disease is an information problem, not just a medical one. It develops silently. It doesn't announce itself. Patients don't know they're drifting off course until they're deep enough in trouble to need expensive, acute intervention. The system built to catch the symptom can't catch the signal.

• 85% of healthcare spend comes from chronic disease
• Healthcare costs are rising at 2.5x the rate of general inflation
• An estimated 50% of total global healthcare spend is pure inefficiency
• Healthcare is a $10 trillion industry -- the same size as all of tech or all of energy

The real problem: misaligned incentives everywhere

If the disease problem is bad, the incentive structure problem is worse. Valenio doesn't shy away from naming it directly -- not as a moral indictment, but as a systems observation that Michael Porter identified twenty years ago.

Hospitals make money when patients stay. Their processes naturally optimize for keeping patients in beds, not for preventing admission in the first place.

Doctors earn when patients are sick. A disease-free patient is revenue-free under most reimbursement models.

Health plans understand that obesity prevention saves money -- but over five to ten years. Their members will likely have switched plans by then. So why invest?

Brokers earn a percentage of the plan cost. Cheaper, healthier plans mean less commission. The incentive runs backwards.

The same structural problem applies in life sciences compliance. Traditional QMS tools were built to help teams pass audits -- not to prevent compliance failures before they happen. The incentive in legacy systems is reactive: respond to findings, patch gaps, survive the inspection. Qualio is built around a different belief: compliance that runs continuously in the background doesn't wait for the audit to tell you something is wrong.

See how continuous compliance works in practice. Explore how Qualio's Agentic Compliance Platform keeps life sciences teams audit-ready every day -- not just when an inspector is walking through the door. Explore the platform or request a demo.

What finally broke the logjam: data, AI, and continuous monitoring

Valenio is specific about the inflection point. It's not one technology -- it's the convergence of three: continuous health monitoring, large longitudinal data sets, and AI frameworks sophisticated enough to make sense of the patterns.

Xenia's early work on diabetes illustrated the opportunity starkly. Two-thirds of diabetes cost, Valenio found, isn't really a medical problem. It's an information problem. Someone is drifting off course, their body isn't telling them, and by the time they arrive at a doctor's office the drift has become a crisis. Add monitoring, add algorithmic pattern recognition, get the patient to a doctor before the crisis -- and outcomes change dramatically.

"We reduced the chances of a person having a heart attack by something like 15%, the chances of dying from diabetes by something like 20%. And it's very, very simple to do and very cheap." -- Mariano Valenio, CEO of Xenia

The mechanism isn't magic. It's the same principle that makes any proactive system outperform a reactive one: catching the signal is dramatically cheaper than treating the consequence.

The life sciences compliance parallel

For life sciences companies -- medical device makers, SaMD developers, pharma and biotech firms -- the structural problem Valenio describes maps precisely onto compliance and quality management.

Most QMS tools were built for the equivalent of acute disease: audits arrive, teams respond, gaps get patched. The system is designed for inspection readiness, not continuous readiness. And just like the healthcare system Valenio describes, the incentives reinforce the behavior: software vendors get renewed when audits are passed, not when quality is genuinely improving.

The regulatory environment is changing this calculus fast. FDA warning letters per 100 inspections are up 43% since 2019. Medical device warning letters alone rose 96% in FY2024. The inspection cadence is compressing. The penalty for reactive compliance is rising.

This is exactly the framework Qualio's Compliance Intelligence platform is built around. Not an episodic QMS that helps you pass audits -- an agentic compliance platform that continuously executes compliance, surfaces risks before they become findings, and gives leadership the real-time visibility to make decisions with accurate data.

From episodic to continuous compliance. See how life sciences teams are moving from audit-driven panic to always-on readiness -- and what that means for speed to market. Read customer stories.

Finding the right spot in the value chain

One of Valenio's most valuable insights is about where you sit in the value chain -- because the same product can fail or succeed depending on who pays for it and why.

Xenia tried selling to patients directly: too fragmented, too difficult. They tried health plans: plans understood the value but wouldn't invest in savings they'd never capture. They eventually found their answer with employers -- organizations with multi-year relationships with their workforce and a genuine incentive to invest in long-term health outcomes.

To make it work, they also had to change how brokers made money: from a percentage of plan cost to a percentage of savings. One structural change unlocked the whole model.

The lesson for health tech founders: finding clinically effective technology is less than half the problem. Finding the right spot in the value chain -- where someone both understands the value and has an aligned incentive to pay for it -- is the harder, more critical work. This is why Qualio positions around business outcomes (velocity, audit readiness, scalable compliance) rather than feature lists. The right buyer cares about the value, not the functionality.

Failing smarter, not faster

Valenio pushes back on one of startup culture's sacred tenets: "move fast and break things." In healthcare, that's not just bad strategy -- it's dangerous.

"You don't have the luxury of failing fast. If you break things, you're going to kill someone. And the other thing is you'll have to go all the way through registration again. So you have to find a way of failing smarter." -- Mariano Valenio, CEO of Xenia

This mirrors the compliance culture challenge Qualio addresses directly. The instinct in tech is to ship at 70-75%, find the bugs in production, and patch forward. In regulated life sciences environments, that standard simply isn't available. The right number of mistakes is zero, because the stakes involve human lives and regulatory records that can't easily be unwound.

Getting a team built on tech culture to genuinely internalize quality-first thinking is a change management challenge as much as a technical one. And it's part of why companies that reach for a QMS tool and get an eQMS checklist often end up in the same posture as before: reactive, gap-patching, inspection-dependent.

Qualio's eQMS is designed for this: ease of use that drives company-wide adoption, not just QA/RA compliance. When the entire organization -- developers, PMs, regulatory affairs -- engages with quality continuously, the culture shifts. Compliance becomes structural, not heroic.

What excites Valenio most -- and should excite all of us

At the end of the conversation, Valenio zooms out. Healthcare is a $10 trillion industry. Roughly half of that spend is pure inefficiency. If that inefficiency were eliminated, the savings could fund healthcare access for the entire world, not just the 50% currently covered.

That's the scope of the prize. And it's not theoretical. Xenia's largest client -- 20,000 lives -- saw a 40% reduction in costs for the highest-risk patients while simultaneously sending those patients to the doctor 7-8% more often. The intervention was earlier. The care was appropriate. The cost was a fraction.

For life sciences companies building the next generation of healthcare products -- SaMD, AI diagnostics, connected devices, drug discovery platforms -- the implication is direct. The tools you use to build those products, manage compliance, and move through regulatory pathways matter not just for your business. They matter for how fast breakthrough products reach patients.

Compliance shouldn't be the bottleneck on treatments and devices that could change lives. That's the belief behind the Qualio platform -- and it's exactly what Valenio is articulating for health tech at large.

Ready to move from reactive to continuous compliance? See how Qualio's Agentic Compliance Platform helps life sciences companies build faster, stay audit-ready, and scale without the compliance tax. Request a demo, explore the platform, or read customer stories.